What is the role of RotaTeq in the prevention of bacterial gastroenteritis?

Updated: Jul 17, 2018
  • Author: Jennifer Lynn Bonheur, MD; Chief Editor: BS Anand, MD  more...
  • Print
Answer

Clinical trials of RotaTeq demonstrated prevention of 74% of all rotavirus gastroenteritis cases, of nearly all severe rotavirus gastroenteritis cases, and of nearly all hospitalizations. A previously marketed rotavirus vaccine (RotaShield) was associated with intussusception, but RotaTeq did not show an increased risk compared with placebo in clinical trials.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!